Dr. Craig Koniver - The Godfather of Peptides | SRS #330
A wide-ranging interview with a South Carolina wellness physician who describes his peptide practice, with the peptide material in the last third and the rest on health philosophy.
With Craig Koniver, Shawn Ryan
Key moments
Tap a moment to play the video from there.
- 3:11Five habits for a healthy 45-year-oldKoniver lists sleep, mindset, CoQ10, hormone testing and peptides as his top five, and says people should avoid piling on every supplement or biohack.
- 18:58The 2020 blood clot storyHe recounts a portal vein thrombosis at age 46, a scare over a pancreatic mass that was not on the next scan, and a blood thinner he still takes.
- 30:50Why he distrusts the healthcare modelKoniver describes the 1910 Flexner report and argues medical training centers on prescribing drugs and demanding trial evidence.
- 1:07:14The three traps in medicineHe names the pill push, the supplement shuffle and the biohacker influencer model, and questions routine screening such as full body MRI and PSA tests.
- 1:16:58Mitochondria, NAD and methylene blueKoniver explains how he thinks NAD, CoQ10 and methylene blue support cellular energy and says he has overseen a very large number of NAD treatments.
- 1:41:32What peptides are and the categoriesHe defines peptides, describes growth hormone releasing and anti-inflammatory groups, and discusses BPC-157 with Ryan's shoulder as an example.
- 1:46:05FDA and compounded peptidesKoniver says an FDA meeting that week would decide whether peptides can still be compounded, and contrasts pharmacy compounding with gray-market sourcing.
- 1:53:17Nervous system and mitochondrial peptidesHe describes Russian-developed peptides used as nasal sprays, a neuropeptide a colleague's father used after a stroke, and SS-31 for mitochondrial structure.
- 2:01:55GLP-1 drugs and other therapiesKoniver calls semaglutide a reliable weight loss tool when used slowly, notes loss of pleasure at higher doses, then covers ozone and plasmapheresis.
What the video says
Shawn Ryan interviews Craig Koniver, a physician who runs a wellness practice in Charleston and is introduced as having administered more than 50,000 peptide treatments. Most of the two hours is general: Koniver tells the story of a 2020 portal vein thrombosis, criticizes the conventional healthcare system, discusses ivermectin and cancer screening, and describes what he calls an outer war of environmental toxins and an inner war of attention and stress.
The peptide discussion starts around the 101 minute mark. Koniver defines peptides as chains of 40 or fewer amino acids and likens them to whispering to cells, in contrast to pharmaceuticals as a sledgehammer. He walks through categories he uses in his practice: growth hormone releasing peptides, anti-inflammatory peptides such as BPC-157, nervous system peptides given as nasal sprays or injections, and mitochondrial peptides such as SS-31. Ryan describes his own shoulder improving on a combination that included BPC-157, and Koniver describes a patient who reported being fully better after two intravenous BPC treatments.
Koniver also spends time on regulation. He says the FDA was meeting that week on whether these peptides can stay on the list of compounded drugs, argues that pharmacy compounding is safer than gray-market online sources, and says he has urged officials to create a path for evaluating compounds with a long safety record. Earlier, he gives NAD and methylene blue as his preferred tools for mitochondrial energy.
The closing stretch covers hormones, semaglutide-type GLP-1 drugs, ozone, plasmapheresis, PEMF and heart rate variability. Throughout, Koniver leans on his own clinical observation rather than published trials, and says he trusts individualized trial and feedback over standard protocols. Listeners wanting dosing or study data will not find it here.
On each compound
BPC-1571:44:05
Koniver describes BPC-157 as anti-inflammatory for tendons and ligaments and says a patient with a forearm injury reported being 100% better after two intravenous treatments. Ryan says his own shoulder range of motion improved on a combination that included it.
See how your DNA reads BPC-157NAD+1:16:58
Koniver says he prefers NAD given by IV over precursors and has seen strong responses, including a veteran whose symptoms he says resolved after two treatments. He acknowledges it does not work for everyone and that NAD levels cannot be measured.
See how your DNA reads NAD+SS-311:55:20
Koniver says SS-31 binds at the same mitochondrial site as methylene blue and helps keep the mitochondria's shape and architecture intact.
See how your DNA reads SS-31Semax1:53:17
Assuming the captions refer to Semax, Koniver says it was developed in Russia for stroke and brain injury, and that he combines it with its cousin in a nasal spray he calls a natural Adderall. He says it is not perfect or for everyone.
See how your DNA reads SemaxCerebrolysin1:54:48
Koniver says a neuropeptide the captions render as cerebral was used by his nurse practitioner's father after a stroke, and that she described a strong recovery.
See how your DNA reads CerebrolysinSemaglutide2:01:55
Koniver calls semaglutide the most reliable weight loss tool right now when started at a low dose and increased slowly. He says he sees loss of pleasure in some people at higher doses and that some patients overshoot.
See how your DNA reads Semaglutide“peptides as like whispering to your cells and pharmaceuticals like a sledgehammer”
What this video doesn’t settle
- Every peptide result is Koniver's clinical observation or a single patient's report, with no control group or published data cited.
- Koniver says he has not seen cancer, blood clots or heart problems in his peptide patients, but this is his own experience and the video offers no systematic safety data.
- Koniver says the FDA meeting on compounding was happening that week, but the video does not give the outcome.
Questions this video answers
What does Koniver say about BPC-157?
He describes it as anti-inflammatory for soft tissue and says he has patients who reported improvement in tendon and forearm problems. Host Shawn Ryan says his own shoulder improved on a combination that included it. These are individual reports, not trial data.
What does Koniver say about the FDA and compounded peptides?
He says the FDA had removed these peptides from compounding and was meeting that week to reconsider. He argues that gray-market online sources are riskier than FDA-registered compounding pharmacies, and that the agency needs a path for evaluating compounds with a long safety record.
How does Koniver compare peptides with pharmaceuticals?
He describes peptides as signaling molecules that work with a person's biology, comparing them to whispering to cells, and pharmaceuticals as a sledgehammer. He says he starts with safety, individualizes dosing and asks patients for feedback.
What does Koniver say about GLP-1 drugs?
He says semaglutide-type drugs are a reliable weight loss tool if started low and increased gradually, and that he monitors patients closely. He also reports seeing reduced enjoyment of food, sex and drinks in some people at higher doses.
Which peptide categories does Koniver discuss?
He covers growth hormone releasing peptides, anti-inflammatory peptides, nervous system peptides, mitochondrial peptides and circadian peptides. He names examples in each group but gives no doses or protocols.
Video by Shawn Ryan Show on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
